Viking Therapeutics (VKTX) Total Current Liabilities (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Total Current Liabilities data on file, last reported at $106.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 443.22% year-over-year to $106.3 million; the trailing twelve-month figure through Mar 2026 stood at $106.3 million (up 443.22% YoY), and the FY2025 full-year result was $76.7 million, up 179.67% from the prior year.
• Total Current Liabilities grew to $106.3 million in Q1 2026, from $76.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $106.3 million in Q1 2026 to a low of $11.3 million in Q1 2022.
• A 5-year average of $29.1 million and a median of $21.9 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 40.28% in 2025 and jumped 443.22% in 2026, its largest moves.
• Tracing VKTX's Total Current Liabilities over 5 years: stood at $21.9 million in 2022, then declined by 12.81% to $19.1 million in 2023, then soared by 43.26% to $27.4 million in 2024, then jumped by 179.67% to $76.7 million in 2025, then soared by 38.68% to $106.3 million in 2026.
• Business Quant data shows VKTX's Total Current Liabilities at $106.3 million in Q1 2026, $76.7 million in Q4 2025, and $26.1 million in Q3 2025.